FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP

Fortress Biotech, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.87+0.00 (0.00%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2011 to 2025

66.9%−1.1 pts over 5 years

-111.0%+95.7 pts over 5 years

10.8%+112.8 pts over 5 years

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	+9.7%	-5.8%	+6.8%	+53.6%
Gross profit	+15.1%	-2.0%	+6.4%	+47.6%

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	-115.6%	-73.5%	18.8%
Return on assets	-38.1%	-16.6%	4.1%
Current ratio	1.94	5.14	2.49
Debt to equity	0.59	0.52	1.05
Net debt to EBITDA	0.92×	–	–
Interest coverage	-17.8×	-6.2×	-6.9×
Inventory turnover	7.8×	12.9×	1.7×
Capex to revenue	38.7%	4.2%	–
Diluted shares	3M	5M	28M

Return on equity split into margin, efficiency and leverage

Net margin10.8%

Asset turnover0.38×

Equity multiplier4.54×

Return on equity, FY202518.8%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	10.8%	0.38×	4.54×	18.8%
FY2024	-79.8%	0.37×	6.88×	-203.2%
FY2023	-71.7%	0.37×	7.19×	-188.7%
FY2022	-114.3%	0.22×	4.59×	-115.1%
FY2021	-94.1%	0.19×	3.49×	-61.9%
FY2020	-102.0%	0.16×	4.42×	-73.5%
FY2019	-109.1%	0.20×	13.09×	-284.7%
FY2018	-313.0%	0.14×	7.11×	-309.2%
FY2017	-387.8%	0.08×	4.58×	-146.9%
FY2016	-334.3%	0.11×	3.03×	-115.6%

Parsed from the XBRL in Fortress Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Oct 10, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FBIO.

Revenue growth15.5% · median 20.9%

Gross margin65.6% · median 78.3%

Operating margin-42.9% · median -14.2%

Net margin163.3% · median -13.8%

Advertisement
300 × 250